Emmaus Life Sciences, Inc. 10-Q

Item 5. Other Information Related Party Loans Over the period January 1, 2022 through June 30, 2022, certain of the Company’s directors and executive officers loaned the Company an aggregate of $2.1million to augment the Company’s working capital as reflected in the following table (in thousands): 26 Principal Amounts Annual Interest Rate Term Soomi Niihara (1) $ 300 12% Due on Demand Yasushi Nagasaki (2) $ 50 10% Due on Demand Hope International Hospice, Inc. (1) $ 350 10% Due on Demand Hope International Hospice, Inc. (1) $ 210 10% Due on Demand Soomi Niihara (1) $ 100 10% Due on Demand Soomi Niihara (1) $ 200 10% Due on Demand Osato Medical Clinic (3) $ 250 12% Due on Demand Hope International Hospice, Inc. (1) $ 150 12% Due on Demand Hope International Hospice, Inc. (1) $ 150 12% Due on Demand Wei Pei Zen (2) $ 200 10% Due on Demand Willis Lee (2) $ 45 10% Due on Demand Hope International Hospice, Inc. (1) $ 40 10% Due on Demand (1) Soomi Niihara is Dr. Niihara’s wife. Dr. Niihara, a Director and the Chairman, and Chief Executive Officer of the Company, is also a director and the Chief Executive Officer of Hope International Hospice, Inc., which is wholly owned by him and his wife. (2) Officer or director. (3) Dr. Osato, a director of Emmaus, and his wife are the sole owners of Osato Medical Clinic. 27 Item 6. Exhibits (a) Exhibits Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Filed/ Furnished 31.1 Certification of Chief Executive Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * 31.2 Certification of Chief Financial Officer pursuant of Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * 32.1 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ** 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. 28 EMMAUS LIFE SCIENCES, INC. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Emmaus Life Sciences, Inc. Dated: August 15, 2022 By: /s/ Yutaka Niihara Name: Yutaka Niihara, M.D., M.P.H. Its: Chief Executive Officer By: /s/ Yasushi Nagasaki Name: Yasushi Nagasaki Its: Chief Financial Officer 29